To describe the current management of diffuse diabetic macular edema (DDME).
Methods.
Review and discussion of the literature regarding DDME.
Results.
Diffuse diabetic macular edema is a condition that can be managed by means of several treatment options, including focal/grid laser photocoagulation, intravitreal or periocular corticosteroids, intravitreal anti-vascular endothelial growth factor (VEGF), and vitrectomy with or without internal limiting membrane peeling.
Conclusions.
Even though there is no randomized clinical trial specifically designed to assess the best treatment approach for DDME, new therapeutic approaches based on intravitreal injections of corticosteroid and anti-VEGF molecules offer new hope for its management.
BandelloF., ParodiM.B., LanzettaP.Diabetic macular edema. Dev Ophthalmol2010; 47: 73–110.
2.
The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993; 329: 977–86.
3.
The Diabetes Control and Complications Trial Research Group.The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes1995; 44: 968–83.
4.
The Diabetes Control and Complications Trial Research Group.The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes1996; 45: 1289–98.
5.
The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. Arch Ophthalmol1995; 113: 36–51.
6.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998; 352: 837–53.
7.
UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998; 317: 708–13.
8.
MatthewsD.R., StrattonI.M., AldingtonS.J.Risk of progression of retinopathy and visual loss related to tight control of blood pressure in Type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol2004; 122: 1631–40.
9.
Diabetic Retinopathy Study Research Group.Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology1981; 88: 583–600.
10.
Early Treatment Diabetic Retinopathy Study Research Group.Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol1985; 103: 1796–806.
11.
BresnickG.H.Diabetic macular edema: a review. Ophthalmology1986; 93: 989–97.
BandelloF., ParodiM.B., TremoladaG.Steroids as part of combination treatment: the future for the management of macular edema?Ophthalmologica2010; 224(Suppl 1): 41–5.
14.
AntonettiD.A., WolpertE.B., DeMaioL., HarhajN.S., ScadutoR.C.Jr.. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem2002; 80: 667–77.
15.
BrooksH.L.Jr., CaballeroS.Jr., NewellC.K.Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol2004; 122: 1801–7.
16.
FischerS., RenzD., SchaperW., KarliczekG.F.In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol2001; 411: 231–43.
17.
JonasJ.B., SofkerA.Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol2001; 132: 425–7.
18.
GilliesM.C., SutterF.K., SimpsonJ.M., LarssonJ., AliH., ZhuM.Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-con-trolled, randomized clinical trial. Ophthalmology2006; 113: 1533–8.
19.
JonasJ.B., KreissigI., SofkerA.Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol2003; 121: 57–61.
20.
AudrenF., ErginayA., HaouchineB.Intravitreal triamcinolone acetonide for diffuse macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand2006; 84: 624–30.
21.
MassinP., AudrenF., HaouchineB.Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology2004; 111: 218–24.
22.
BeerP.M., BakriS.J., SinghR.J.Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology2003; 110: 681–6.
23.
SpandauU.H., DerseM., Schmitz-ValckenbergP., PapoulisC., JonasJ.B.Dosage dependency of intravitreal triamcinolone acetonide as treatment for diabetic macular oedema. Br J Ophthalmol2005; 89: 999–1003.
24.
JonasJ.B., DegenringR.F., KamppeterB.A., KreissigI., AkkoyunI.Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol2004; 138: 158–60.
25.
JonasJ.B., SpandauU.H., KamppeterB.A.Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology2006; 113: 800–4.
26.
ChanC.K.M., MohamedS., ShanmugamM.P.Decreasing efficacy of repeated intravitreal triamcinolone injections in diabetic macular oedema. Br J Ophthalmol2006; 90: 1137–41.
27.
ShimuraM., NakazawaT., YasudaK.Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular edema. Br J Ophthalmol2007; 91: 449–54.
28.
KangS.W., SaH.S., YoonH.Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol2006; 124: 653–8.
29.
TuncM., OnderH.I., KayaM.Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema. Ophthalmology2005; 112: 1086–91.
30.
FigueroaM.S., ContrerasI., NovalS.Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina2008; 28: 420–6.
31.
NeufeldG., CohenT., GengrinovitchS.Vascular endothelial growth factor (VEGF) and its receptors. FASEB J1999; 13: 9–22.
32.
GrantM.B., AfzalA., SpoerriP.The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs2004; 13: 1275–93.
33.
PlateK.H., BreierG., WeichH.A., RisauW.Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature1992; 359: 845–8.
34.
ShweikiD., ItinA., SofterD., KeshetE.Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature1992; 359: 843–5.
35.
AielloL.P., AveryR.L., ArriggP.G.Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med1994; 331: 1480–7.
36.
GardnerT.W., AntonettiD.A., BarberA.J.Diabetic retinopathy: more than meets the eye. Surv Ophthalmol2002; 47(Suppl 2): S253–62.
37.
ArevaloJ.F., SanchezJ.G., WuL., Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for diffuse diabetic macular edema: The Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology2009; 116: 1488–97.
38.
LamD.S., LaiT.Y., LeeV.Y., ChanC.K., LiuD.T., MohamedS., LiC.L.Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina2009; 29: 292–9.
KookD., WolfA., KreutzerT.Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina2008; 28: 1053–60.
41.
KreutzerT.C., AI SaeidiR., KookD.Comparison of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular edema. Ophthalmologica2010; 224: 258–64.
42.
RenschF., UlrichH.M., SpandauA.W., JonasJ.B.Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide. Acta Ophthalmol2010; 88: e36–7.
43.
ShimuraM., NakazawaT., YasudaK.Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol2008; 145: 854–61.
44.
PaccolaL., CostaR.A., FolgosaM.S.Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol2008; 92: 76–80.
45.
SolaimanK.A., DiabM.M., Abo-EleninM.Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina Epub2010 Sep 10.
46.
YanyaliA., HorozogluF., CelikE., NohutcuA.F.Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina2007; 27: 557–66.
47.
StolbaU., BinderS., GruberD.Vitrectomy for persistent diffuse diabetic macular edema. Am J Ophthalmol2005; 140: 295–301.
48.
ThomasD., BunceC., MoormanC., LaidlawD.A.A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema. Br J Ophthalmol2005; 89: 81–6.
49.
PatelJ.I., HykinP.G., SchadtM.Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs macular argon photocoagulation. Eye2006; 20: 873–81.
50.
KumarA., SinhaS., AzadR.Comparative evaluation of vitrectomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol2007; 245: 360–8.
